Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Newer formulations of intravenous iron: a review of their chemistry and key safety aspects – hypersensitivity, hypophosphatemia, and cardiovascular safety
Irina Blumenstein, Satish Shanbhag, Peter Langguth, et al.
Expert Opinion on Drug Safety (2021) Vol. 20, Iss. 7, pp. 757-769
Open Access | Times Cited: 63

Showing 1-25 of 63 citing articles:

Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle
Yue Huang, Jessica C. Hsu, Hyun Koo, et al.
Theranostics (2021) Vol. 12, Iss. 2, pp. 796-816
Open Access | Times Cited: 149
Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial
Heinz Zoller, Myles Wolf, Irina Blumenstein, et al.
Gut (2022) Vol. 72, Iss. 4, pp. 644-653
Open Access | Times Cited: 59
Expert consensus guidelines: Intravenous iron uses, formulations, administration, and management of reactions
Layla Van Doren, Marlene M. Steinheiser, Kristen Boykin, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 7, pp. 1338-1348
Open Access | Times Cited: 12
The Story of Ferumoxytol: Synthesis Production, Current Clinical Applications, and Therapeutic Potential
Mengmeng Long, Yan Li, Hongliang He, et al.
Advanced Healthcare Materials (2023) Vol. 13, Iss. 6
Closed Access | Times Cited: 19
Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose
Benedikt Schaefer, Heinz Zoller, Myles Wolf
The Journal of Clinical Endocrinology & Metabolism (2021) Vol. 107, Iss. 4, pp. 1009-1019
Open Access | Times Cited: 36
Recent and Emerging Therapies for Iron Deficiency in Anemia of CKD: A Review
Jonathan W. Bazeley, Jay B. Wish
American Journal of Kidney Diseases (2021) Vol. 79, Iss. 6, pp. 868-876
Open Access | Times Cited: 33
Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in England
Tariq Iqbal, Nicholas A. Kennedy, Anjan Dhar, et al.
Journal of Medical Economics (2024) Vol. 27, Iss. 1, pp. 392-403
Open Access | Times Cited: 5
Anemia in Chronic Renal Disease
Larry A. Greenbaum
Springer eBooks (2023), pp. 1603-1630
Closed Access | Times Cited: 12
Hypersensitivity to Intravenous Iron Preparations
Silvia Caimmi, Giuseppe Crisafulli, Fabrizio Franceschini, et al.
Children (2022) Vol. 9, Iss. 10, pp. 1473-1473
Open Access | Times Cited: 17
Lessons learned from immunological characterization of nanomaterials at the Nanotechnology Characterization Laboratory
Marina A. Dobrovolskaia
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 17
Interpreting Iron Homeostasis in Congenital and Acquired Disorders
Natalia Scaramellini, Dania Fischer, R. Anand, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 3, pp. 329-329
Open Access | Times Cited: 10
Intravenous iron in chronic kidney disease without anaemia but iron deficiency: A scoping review
Abdulrahman Alsunaid, Sebastian Spencer, Sunil Bhandari
World Journal of Nephrology (2025) Vol. 14, Iss. 1
Closed Access
Ferric Carboxymaltose (FCM)–Associated Hypophosphatemia (HPP): A Systematic Review
Joseph Magagnoli, Kevin Knopf, William J.M. Hrushesky, et al.
American Journal of Hematology (2025)
Open Access
Understanding and Managing Infusion Reactions and Hypophosphataemia With Intravenous Iron—A Nurses' Consensus Paper
Aileen Fraser, V Cairnes, Edwin J. Mikkelsen, et al.
Nursing Open (2025) Vol. 12, Iss. 4
Open Access
Applications and Efficacy of Iron Oxide Nanoparticles in the Treatment of Brain Tumors
London Varalli, Reed Berlet, Eric Abenojar, et al.
Pharmaceutics (2025) Vol. 17, Iss. 4, pp. 499-499
Open Access
UK kidney association clinical practice guideline: update of anaemia of chronic kidney disease
Sunil Bhandari, Sebastian Spencer, Ben Oliveira, et al.
BMC Nephrology (2025) Vol. 26, Iss. 1
Open Access
Initial effectiveness and safety data on intravenous ferric derisomaltose for iron deficiency anaemia management in paediatric gastroenterology patients: a multicentre retrospective cohort study
Laura Gianolio, S Emmitt, Maureen Nwabueze, et al.
Archives of Disease in Childhood (2025), pp. archdischild-328215
Closed Access
Iron Deficiency in CKD Without Concomitant Anemia
Jay B. Wish, Stefan D. Anker, Javed Butler, et al.
Kidney International Reports (2021) Vol. 6, Iss. 11, pp. 2752-2762
Open Access | Times Cited: 23
Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study
Hiroshi Kawabata, Takeshi Tamura, Soichiro Tamai, et al.
International Journal of Hematology (2022) Vol. 116, Iss. 5, pp. 647-658
Open Access | Times Cited: 15
Hypophosphataemia risk associated with ferric carboxymaltose in heart failure: A pooled analysis of clinical trials
Giuseppe Rosano, Kamyar Kalantar‐Zadeh, Ewa A. Jankowska
ESC Heart Failure (2023) Vol. 10, Iss. 2, pp. 1294-1304
Open Access | Times Cited: 9
Iron Treatment in Patients with Iron Deficiency Before and After Metabolic and Bariatric Surgery: A Narrative Review
Jila Kaberi‐Otarod, Christopher D. Still, G. Craig Wood, et al.
Nutrients (2024) Vol. 16, Iss. 19, pp. 3350-3350
Open Access | Times Cited: 3
IV iron formulations and use in adults
Layla Van Doren, Michael Auerbach
Hematology (2023) Vol. 2023, Iss. 1, pp. 622-629
Closed Access | Times Cited: 7
Hypophosphatemia attenuates improvements in vitality after intravenous iron treatment in patients with inflammatory bowel disease
Jakob Bue Bjørner, Nicholas A. Kennedy, Stefan Lindgren, et al.
Quality of Life Research (2024) Vol. 33, Iss. 8, pp. 2285-2294
Open Access | Times Cited: 2
Intravenous Iron Versus Oral Iron Administration for the Treatment of Iron Deficiency Anemia: A Patient-Preference Study
Ranya Ghamri, Hadeel H. Alsulami
Cureus (2024)
Open Access | Times Cited: 2
Incidence and predictors of hypophosphataemia after ferric carboxymaltose use—A 3‐year experience from a single institution in Singapore
Zachary Chu, Tim Cushway, Marc Wong, et al.
British Journal of Haematology (2023) Vol. 202, Iss. 6, pp. 1199-1204
Closed Access | Times Cited: 6
Page 1 - Next Page

Scroll to top